Sugi Predict

Sugi Predict / Compounds / SCHEMBL1600588

SCHEMBL1600588

SCHEMBL1600588

COc1c(N)cc(C(C)(C)C)cc1C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 3/20 0.44
▸ RXRA P19793 2/20 0.40
▸ RARG P13631 1/20 0.40
▸ PPARG P37231 1/20 0.40
▸ ALDH1A1 P00352 5/20 0.40
▸ KDM4E B2RXH2 4/20 0.40
▸ HPGD P15428 2/20 0.40
▸ AKR1C3 P42330 1/20 0.40
▸ AKR1C2 P52895 1/20 0.40
▸ TDP1 Q9NUW8 3/20 0.40
▸ RXRB P28702 2/20 0.40
▸ MAPT P10636 2/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ PKM P14618 2/20 0.37
▸ GAA P10253 1/20 0.37
▸ RECQL P46063 1/20 0.37
▸ RXRG P48443 1/20 0.37
▸ ELANE P08246 1/20 0.36
▸ CD69 Q07108 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1404705 0.87 RARG (0.38) RXRARARGPPARGALDH1A1KDM4E
SCHEMBL1303731 0.85 CFTR (0.49) HSD17B10RXRARARGPPARGALDH1A1
SCHEMBL7786427 0.83 RXRB (0.49) HSD17B10RXRARARGPPARGALDH1A1
SCHEMBL5118526 0.83 MAPT (0.38) RXRARARGPPARGALDH1A1KDM4E
SCHEMBL688542 0.83 RARG (0.36) RXRARARGPPARGALDH1A1KDM4E
SCHEMBL9187455 0.81 RXRB (0.47) HSD17B10RXRARARGPPARGALDH1A1
SCHEMBL5665923 0.81 RXRA (0.56) HSD17B10RXRARARGPPARGAKR1C3
SCHEMBL9192206 0.80 RXRA (0.55) HSD17B10RXRARARGPPARGAKR1C3
SCHEMBL4727360 0.80 HSD17B10 (0.65) HSD17B10RXRARARGPPARGALDH1A1
SCHEMBL690103 0.80 POLB (0.44) HSD17B10RXRARARGPPARGALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113717162-A Urea derivatives as kinase inhibitors 奥苏拉收购有限公司 2021-11-30 — — CN disclosed
EP-2981535-B1 UREA DERIVATIVES USEFUL AS KINASE INHIBITORS TOPIVERT PHARMA LTD (GB) 2020-12-16 — — EP disclosed
US-10435361-B2 Kinase inhibitors TOPIVERT PHARMA LIMITED (GB) 2019-10-08 — — US disclosed
US-20180044288-A1 KINASE INHIBITORS OXULAR ACQUISITIONS LIMITED (GB) 2018-02-15 — — US disclosed
US-9890185-B2 Urea derivatives useful as kinase inhibitors RESPIVERT LIMITED (GB) 2018-02-13 — — US disclosed
US-9790174-B2 Kinase inhibitors RESPIVERT LIMITED (GB) 2017-10-17 — — US disclosed
US-20160376232-A1 KINASE INHIBITORS OXULAR ACQUISITIONS LIMITED (GB) 2016-12-29 — — US disclosed
US-20160318958-A1 UREA DERIVATIVES USEFUL AS KINASE INHIBITORS OXULAR ACQUISITIONS LIMITED (GB) 2016-11-03 — — US disclosed
US-9481648-B2 Kinase inhibitors RESPIVERT LIMITED (GB) 2016-11-01 — — US disclosed
EP-3083604-A1 UREA DERIVATIVES USEFUL AS KINASE INHIBITORS Respivert Limited (GB) 2016-10-26 — — EP disclosed
US-20100093734-A1 CYTOKINE INHIBITORS ITHERX PHARMACEUTICALS, INC. (US) 2010-04-15 — — US disclosed
US-20100093734-A1 CYTOKINE INHIBITORS ITHERX PHARMACEUTICALS, INC. (US) 2010-04-15 — — US disclosed
US-20100093734-A1 CYTOKINE INHIBITORS ITHERX PHARMACEUTICALS, INC. (US) 2010-04-15 — — US disclosed
US-20100093735-A1 CYTOKINE INHIBITORS ITHERX PHARMACEUTICALS, INC. (US) 2010-04-15 — — US disclosed
US-20100093735-A1 CYTOKINE INHIBITORS ITHERX PHARMACEUTICALS, INC. (US) 2010-04-15 — — US disclosed
US-20100093735-A1 CYTOKINE INHIBITORS ITHERX PHARMACEUTICALS, INC. (US) 2010-04-15 — — US disclosed
EP-1670787-A4 CYTOKINE INHIBITORS KEMIA INC (US) 2009-04-22 — — EP disclosed
EP-1670787-A2 CYTOKINE INHIBITORS Kemia, INC. (US) 2006-06-21 — — EP disclosed
US-20050107399-A1 Cytokine inhibitors KEMIA, INC. 2005-05-19 — — US disclosed
WO-2005023761-A2 CYTOKINE INHIBITORS KEMIA, INC. (US) 2005-03-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107399-A1 Cytokine inhibitors TNF, IL1RN, IL1A HSD17B10 2097/4885RXRA 3398/4885RARG 2122/4885
US-20160318958-A1 UREA DERIVATIVES USEFUL AS KINASE INHIBITORS SYK, UACA, YES1 HSD17B10 4812/4885RXRA 1154/4885RARG 1288/4885
US-20180044288-A1 KINASE INHIBITORS SYK, LYN, BTK HSD17B10 4720/4885RXRA 1759/4885RARG 3974/4885
US-20100093734-A1 CYTOKINE INHIBITORS TNF, IL1RN, IL1A HSD17B10 2097/4885RXRA 3398/4885RARG 2122/4885
US-20160376232-A1 KINASE INHIBITORS LYN, SYK, LCK HSD17B10 3142/4885RXRA 4049/4885RARG 3932/4885
US-20100093735-A1 CYTOKINE INHIBITORS TNF, IL1RN, IL1A HSD17B10 2097/4885RXRA 3398/4885RARG 2122/4885
US-10435361-B2 Kinase inhibitors SYK, LYN, BTK HSD17B10 4720/4885RXRA 1759/4885RARG 3974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.